Skip to search formSkip to main contentSkip to account menu

MDL 28170

Known as: MDL-28170, MDL28170 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
SUMMARY In this paper, we aimed to explore the effects of the calpain inhibitor III (MDL28170) and to detect calpain-like… 
Highly Cited
2008
Highly Cited
2008
Neurodegeneration induced by the NMDA receptor antagonist, phencyclidine (PCP), has been used to model the pathogenesis of… 
2008
2008
Although calpain (calcium-activated cysteine protease) inhibition represents a rational therapeutic target for spinal cord injury… 
2007
2007
Following contusive spinal cord injury (SCI), calpain activity is dramatically increased and remains elevated for days to weeks… 
2007
2007
We previously reported that exogenous cardiotrophin‐1 (CT‐1), a member of the IL‐6 family of cytokines, exerts hepatoprotective… 
2007
2007
Enhanced activity of the dopaminergic system originating in the ventral tegmental area is implicated in addictive and psychiatric… 
2005
2005
Aberrant calpain activation is a key mediator of neuron death. We examined the cell-permeable calpain inhibitor MDL28170 in the… 
2003
2003
Calpains (calcium-activated cysteine proteases) are strongly implicated in the secondary damage that follows contusion injury to…